



Helsingborg December 17, 2024

Press release

Aqilion to present at Biotech Showcase™ during JP Morgan week in San Fransisco

AQILION AB (publ) today announced that it is presenting at Biotech Showcase 2025. Sarah Fredriksson, CEO, and Johan Lund, CSO, will attend the partnering event and present the latest pipeline developments. During the week the Aqilion team will present new preclinical data from the AQ312 program, an AhR agonist for ulcerative colitis. The latest updates from the AQ280 program and the clinical development moving towards a phase 2 study in patients with Eosinophilic esophagitis will also be presented.

This year, registered attendees can view company presentations live, and also access a recorded version. Sarah Fredriksson will be presenting Aqilion at Biotech Showcase January 14 at 11 am.

“I am looking forward to the opportunity to meet investors and potential partners during the JP Morgan week. It is an exceptionally good opportunity to present new results and to interact with an audience that holds unique industry knowledge and excellence. It is my pleasure to present AQILION and our ambitions and goals for the future“ said Sarah Fredriksson, CEO of Aqilion.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.

“We are delighted that AQILION will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime opportunity for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of human health.”

For more information, please contact:

Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Biotech Showcase™

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 17th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

About Aqilion

Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases.

We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The innovation approach is based on solid scientific grounds, in disease areas where we, with reasonable assumptions, can understand the underlying biology, clinical relevance of the mechanism, potential patient benefit and the likelihood for finding a partner.

The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion executes its development programs in a partly virtual organization in close collaboration with selected partners, with specific expertise in drug development.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com